Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249234219> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2249234219 endingPage "10586" @default.
- W2249234219 startingPage "10586" @default.
- W2249234219 abstract "10586 Background: the availability of chemotherapeutic drugs given by oral route represents a step forward in the management of cancer patients (pts). Vinorelbine and capecitabine have demonstrated established efficacy in metastatic breast cancer (MBC) with distinct mechanism of action. Oral vinorelbine (OVRL) interacts with tubulin and capecitabine (XLD) acts through antimetabolite properties of 5FU. OVRL is rapidly absorbed (1.5- 3h) with elimination half-life around of 40h. No pharmacokinetic interaction was found between these two compounds and its metabolites according to a recent phase I trial. Methods: The treatment schedule was 60 mg/m 2 of OVRL on day 1 and 8; XLD 1000 mg/ m 2 bid from day 1 to 14 every 3 weeks. Cycles were repeated if ≥1000/mm 3 neutrophils and ≥100000 platelets. In case of ≥ Grade (G) 3 haematological and non haematological toxicity dose adjustments were planned: OVRL from 60 mg/ m 2 50 or 40 mg/ m 2 and XLD from 1000 mg/ m 2 to 900 mg/m 2 or 750 mg/ m 2 b.i.d. Results: Between June 2003 to December 2005, 29 advanced breast cancer pts were included in this trial. Median age: 64 years [range (42–85)]. PS0: 60, PS1: 40. Eight pts, 9 pts and 12 pts received the combination as 1 st line, 2 nd line and ≥3 rd line treatment respectively. A median of 5 cycles [1–30] was given. No G 3/4 haematological toxicity was observed. One pt. suffered from G3 diarrhoea, G2 mild diarrhoea and abdominal pain was reported after ORVRL lasting 24 hours. No hand-foot syndrome has been observed.Out of 18 evaluable pts, 17 had clinical benefit: 1 CR, 4 PR and 12 SD (90% of tumour control). Conclusion: Oral vinorelbine and capecitabine combination is well tolerated and active in MCB pts allowing long-term treatment in ambulatory setting avoiding central venous line and infusions; therefore, this combination should be investigated in early lines of treatment. Final results will be presented during the meeting. [Table: see text]" @default.
- W2249234219 created "2016-06-24" @default.
- W2249234219 creator A5030661309 @default.
- W2249234219 creator A5031854391 @default.
- W2249234219 creator A5037662144 @default.
- W2249234219 creator A5063935752 @default.
- W2249234219 creator A5074450620 @default.
- W2249234219 creator A5078594252 @default.
- W2249234219 date "2006-06-20" @default.
- W2249234219 modified "2023-10-17" @default.
- W2249234219 title "Oral vinorelbine in combination with capecitabine in advanced breast cancer" @default.
- W2249234219 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.10586" @default.
- W2249234219 hasPublicationYear "2006" @default.
- W2249234219 type Work @default.
- W2249234219 sameAs 2249234219 @default.
- W2249234219 citedByCount "2" @default.
- W2249234219 crossrefType "journal-article" @default.
- W2249234219 hasAuthorship W2249234219A5030661309 @default.
- W2249234219 hasAuthorship W2249234219A5031854391 @default.
- W2249234219 hasAuthorship W2249234219A5037662144 @default.
- W2249234219 hasAuthorship W2249234219A5063935752 @default.
- W2249234219 hasAuthorship W2249234219A5074450620 @default.
- W2249234219 hasAuthorship W2249234219A5078594252 @default.
- W2249234219 hasConcept C112705442 @default.
- W2249234219 hasConcept C121608353 @default.
- W2249234219 hasConcept C126322002 @default.
- W2249234219 hasConcept C141071460 @default.
- W2249234219 hasConcept C143998085 @default.
- W2249234219 hasConcept C2775930923 @default.
- W2249234219 hasConcept C2776694085 @default.
- W2249234219 hasConcept C2777063308 @default.
- W2249234219 hasConcept C2777909004 @default.
- W2249234219 hasConcept C2778239845 @default.
- W2249234219 hasConcept C2778397455 @default.
- W2249234219 hasConcept C2780350996 @default.
- W2249234219 hasConcept C2780456651 @default.
- W2249234219 hasConcept C29730261 @default.
- W2249234219 hasConcept C31760486 @default.
- W2249234219 hasConcept C526805850 @default.
- W2249234219 hasConcept C530470458 @default.
- W2249234219 hasConcept C71924100 @default.
- W2249234219 hasConcept C90924648 @default.
- W2249234219 hasConcept C98274493 @default.
- W2249234219 hasConceptScore W2249234219C112705442 @default.
- W2249234219 hasConceptScore W2249234219C121608353 @default.
- W2249234219 hasConceptScore W2249234219C126322002 @default.
- W2249234219 hasConceptScore W2249234219C141071460 @default.
- W2249234219 hasConceptScore W2249234219C143998085 @default.
- W2249234219 hasConceptScore W2249234219C2775930923 @default.
- W2249234219 hasConceptScore W2249234219C2776694085 @default.
- W2249234219 hasConceptScore W2249234219C2777063308 @default.
- W2249234219 hasConceptScore W2249234219C2777909004 @default.
- W2249234219 hasConceptScore W2249234219C2778239845 @default.
- W2249234219 hasConceptScore W2249234219C2778397455 @default.
- W2249234219 hasConceptScore W2249234219C2780350996 @default.
- W2249234219 hasConceptScore W2249234219C2780456651 @default.
- W2249234219 hasConceptScore W2249234219C29730261 @default.
- W2249234219 hasConceptScore W2249234219C31760486 @default.
- W2249234219 hasConceptScore W2249234219C526805850 @default.
- W2249234219 hasConceptScore W2249234219C530470458 @default.
- W2249234219 hasConceptScore W2249234219C71924100 @default.
- W2249234219 hasConceptScore W2249234219C90924648 @default.
- W2249234219 hasConceptScore W2249234219C98274493 @default.
- W2249234219 hasIssue "18_suppl" @default.
- W2249234219 hasLocation W22492342191 @default.
- W2249234219 hasOpenAccess W2249234219 @default.
- W2249234219 hasPrimaryLocation W22492342191 @default.
- W2249234219 hasRelatedWork W1905409013 @default.
- W2249234219 hasRelatedWork W1987053256 @default.
- W2249234219 hasRelatedWork W2006511892 @default.
- W2249234219 hasRelatedWork W2056528636 @default.
- W2249234219 hasRelatedWork W2089025198 @default.
- W2249234219 hasRelatedWork W2143249269 @default.
- W2249234219 hasRelatedWork W2158652816 @default.
- W2249234219 hasRelatedWork W2275049615 @default.
- W2249234219 hasRelatedWork W4233379803 @default.
- W2249234219 hasRelatedWork W2024508311 @default.
- W2249234219 hasVolume "24" @default.
- W2249234219 isParatext "false" @default.
- W2249234219 isRetracted "false" @default.
- W2249234219 magId "2249234219" @default.
- W2249234219 workType "article" @default.